SCHEMBL4887682

SCHEMBL4887682

CN(CC1C2CN(Cc3cccs3)CC21)C(=O)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
PKM P14618 1/20 0.40
GBA1 P04062 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RIPK1 Q13546 1/20 0.37
DRD4 P21917 3/20 0.37
DRD3 P35462 2/20 0.37
POLB P06746 2/20 0.36
GAA P10253 1/20 0.35
DRD2 P14416 1/20 0.35
CYP3A4 P08684 1/20 0.35
HSD11B1 P28845 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4620168 0.85 CHRM3 (0.41) MAPTALDH1A1SMN1; SMN2GAACHRM2
SCHEMBL4619318 0.85 CHRM3 (0.44) KDM4ECHRM3
SCHEMBL4619338 0.81 CHRM3 (0.38) DRD4DRD2CHRM2CHRM1CHRM3
SCHEMBL4143610 0.80 HRH1 (0.43) SMN1; SMN2POLBGAACHRM2CHRM1
SCHEMBL4617546 0.80 CHRM2 (0.37) ALDH1A1SMN1; SMN2POLBGAACHRM2
SCHEMBL4137463 0.79 CACNA1G (0.42) CHRM3SIGMAR1
SCHEMBL4145807 0.78 CHRM3 (0.40) MAPTKDM4EALDH1A1CHRM2CHRM1
SCHEMBL4618122 0.77 CHRM3 (0.40) MAPTKDM4EALDH1A1CHRM2CHRM1
SCHEMBL4619558 0.76 CHRM2 (0.43) ALDH1A1CHRM2CHRM1CHRM3
SCHEMBL4140154 0.75 ACHE (0.42) KDM4ECHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US claimed
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 MAPT 4274/4885PKM 4349/4885GBA1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.